AtaiBeckley (ATAI)

NasdaqMarket Closed

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company developing novel treatments for mental health disorders. Its work is centred on therapies that aim to act more rapidly, or offer a more convenient treatment experience, than many existing psychiatric medicines. The company’s pipeline is focused on conditions with substantial unmet need, including treatment-resistant depression and social anxiety disorder.

The company’s lead programmes include BPL-003, a mebufotenin benzoate nasal spray being studied for treatment-resistant depression, and VLS-01, a DMT buccal film also being developed for treatment-resistant depression. AtaiBeckley is also advancing EMP-01, an (R)-MDMA hydrochloride candidate for social anxiety disorder. These assets are in Phase 2 clinical development, meaning they are being evaluated for safety, dosing, and signs of efficacy in patient populations before any potential late-stage trials.

AtaiBeckley operates in a fast-evolving area of neuroscience that includes psychedelic-inspired and rapid-acting psychiatric therapies. Its candidates are notable not only for their active compounds but also for their delivery formats, such as nasal spray and buccal film, which are intended to make administration more practical in controlled clinical settings. The company’s strategy depends on generating convincing clinical data, navigating regulatory requirements, and demonstrating that its treatments can be used safely and effectively.

As a development-stage biotech, AtaiBeckley does not resemble a conventional revenue-driven healthcare business. Its valuation is closely linked to clinical trial outcomes, regulatory progress, financing needs, and the commercial potential of new approaches to serious mental health conditions.

7.22USD
+0.04(+0.56%)

Last updated

Market Cap
$2,656,272,822
P/E
P/FCF
P/S
Enterprise Value
Sector
Materials
Industry
Pharmaceutical Preparations
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK, NY, 10119
nasdaq.com

Why Eli Lilly Stock Climbed Today

06 Aug 2026, 10:53 AM
yahoo.com

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

03 Aug 2026, 10:26 AM
yahoo.com

AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued

17 Jul 2026, 22:08 PM
nasdaq.com

Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch

17 Jul 2026, 14:52 PM
yahoo.com

AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly

17 Jul 2026, 12:19 PM
yahoo.com

AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout

17 Jul 2026, 06:59 AM
Stock market

AtaiBeckley stock is soaring, and it has Eli Lilly to thank

17 Jul 2026, 05:58 AM
cnbc.com

Stocks making the biggest moves midday: Manpower, Abbott, UnitedHealth, TSMC & more

17 Jul 2026, 04:06 AM
yahoo.com

Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion

17 Jul 2026, 03:45 AM
yahoo.com

Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover

17 Jul 2026, 01:50 AM
yahoo.com

Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy

17 Jul 2026, 01:23 AM
cnbc.com

Stocks making the biggest moves premarket: UnitedHealth, TSMC, GE Aerospace, J.B. Hunt & more

17 Jul 2026, 00:00 AM
nasdaq.com

Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict

15 Jul 2026, 15:18 PM
yahoo.com

The Race to Commercialize the World’s Most Powerful Psychedelic

15 Jul 2026, 07:00 AM
yahoo.com

3 Psychedelic Stocks With Potential Clinical Trial Catalysts

10 Jul 2026, 18:21 PM
nasdaq.com

What This $496,000 Insider Sale at AtaiBeckley Means Amid Roughly 100% Stock Run

10 Jul 2026, 12:12 PM
globenewswire.com

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

27 May 2026, 22:00 PM
globenewswire.com

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

22 Apr 2026, 22:00 PM
globenewswire.com

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

14 Apr 2026, 22:00 PM
globenewswire.com

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

17 Mar 2026, 23:00 PM
Market Cap
$2,656,272,822
Enterprise Value
P/E
P/B
P/S
EV / EBITDA
EV / Sales
EPS
Dividend Yield
P/FCF
P/CF
Free Cash Flow
ROE
ROA
Debt / Equity
Current Ratio
Quick Ratio
Cash
Avg Volume
Fundamentals Snapshot Price

Financial statements are not available for this listing.

KindFilingDateLink
edgar indexPREM14A — AtaiBeckley Inc.View Filing
edgar indexSCHEDULE 13G — AtaiBeckley Inc.View Filing
edgar indexSCHEDULE 13D/A — AtaiBeckley Inc.View Filing
edgar index8-K — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
eight k text8-K — 8-KView Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index144 — AtaiBeckley Inc.View Filing
form 4Form 4 — HERSHBERG ROBERTView Filing
form 4Form 4 — HERSHBERG ROBERTView Filing
form 4Form 4 — HERSHBERG ROBERTView Filing
form 4Form 4 — HERSHBERG ROBERTView Filing
form 4Form 4 — HERSHBERG ROBERTView Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index144 — AtaiBeckley Inc.View Filing
form 4Form 4 — Kochendoerfer GerdView Filing
form 4Form 4 — Kochendoerfer GerdView Filing
form 4Form 4 — Kochendoerfer GerdView Filing
edgar index144 — AtaiBeckley Inc.View Filing
form 4Form 4 — Craig Kevin JamesView Filing
form 4Form 4 — Craig Kevin JamesView Filing
form 4Form 4 — Craig Kevin JamesView Filing
form 4Form 4 — Craig Kevin JamesView Filing
form 4Form 4 — Craig Kevin JamesView Filing
edgar index8-K — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
eight k text8-K — 8-KView Filing
form 4Form 4 — JOHNSON SABRINA MARTUCCIView Filing
form 4Form 4 — Smiley Andrea HeslinView Filing
form 4Form 4 — Kalali Amir HView Filing
form 4Form 4 — Hoffman John FrancisView Filing
form 4Form 4 — HERSHBERG ROBERTView Filing
form 4Form 4 — Fischer LaurentView Filing
form 4Form 4 — Braunstein ScottView Filing
form 4Form 4 — Braunstein ScottView Filing
form 4Form 4 — Angermayer ChristianView Filing
edgar index8-K — AtaiBeckley Inc.View Filing
eight k text8-K — 8-KView Filing
edgar index8-K — AtaiBeckley Inc.View Filing
edgar index10-Q — AtaiBeckley Inc.View Filing
eight k text8-K — 8-KView Filing
edgar indexDEF 14A — AtaiBeckley Inc.View Filing
edgar indexDEFA14A — AtaiBeckley Inc.View Filing
edgar index4 — AtaiBeckley Inc.View Filing
edgar index144 — AtaiBeckley Inc.View Filing
form 4Form 4 — Craig Kevin JamesView Filing
form 4Form 4 — Craig Kevin JamesView Filing
form 4Form 4 — Craig Kevin JamesView Filing
form 4Form 4 — Craig Kevin JamesView Filing
form 4Form 4 — Craig Kevin JamesView Filing
edgar index4 — AtaiBeckley Inc.View Filing
form 4Form 4 — Apeiron Investment Group Ltd.View Filing
form 4Form 4 — Angermayer ChristianView Filing
form 4Form 4 — Apeiron Investment Group Ltd.View Filing
form 4Form 4 — Angermayer ChristianView Filing
form 4Form 4 — Apeiron Investment Group Ltd.View Filing
form 4Form 4 — Apeiron Investment Group Ltd.View Filing
form 4Form 4 — Angermayer ChristianView Filing